Drug Profile


Alternative Names: IBU-PC; Ibuprofen-PC; Ibuprofen-phosphatidylcholine; PL 1100; Zavryl

Latest Information Update: 21 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PLx Pharma
  • Class Antirheumatics; Antiulcers; Cytoprotectives; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylpropionates
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Inflammation; Pain

Most Recent Events

  • 20 Oct 2017 Phase-II development is ongoing for Pain and Inflammation (associated with Osteoarthritis and Rheumatoid arthritis) (PLx Pharma pipeline, October 2017)
  • 31 Jul 2015 Phase II development is ongoing for Pain and inflammation in USA (PO)
  • 11 Jan 2011 Phase II development is ongoing for Pain and inflammation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top